Aragen Biologics

Aragen Biologics is a leading global contract development and manufacturing organization (CDMO) providing end‑to‑end solutions for the development and manufacture of biologics. Aragen supports animal and human health companies across the full product lifecycle, from early development through late‑stage clinical and commercial supply.

The organization offers fully integrated capabilities including cell line development, upstream and downstream process development, analytical development, formulation, and GMP manufacturing of clinical and commercial drug substance. Aragen has deep expertise in complex biologics such as monoclonal antibodies, bispecifics, Fc‑fusion proteins, and other recombinant proteins, with growing capabilities aligned to next‑generation modalities.

Aragen operates state‑of‑the‑art development and manufacturing facilities supported by experienced scientific, technical, and quality teams with a strong regulatory track record across global markets including the US, Europe, and other key regions. Its modern manufacturing infrastructure is designed to support flexible, scalable production, enabling smooth transitions from clinical to commercial stages.

With a strong focus on scientific rigor, quality, and partnership, Aragen Biologics works closely with clients to de‑risk development, accelerate timelines, and deliver robust, compliant manufacturing solutions. By combining deep technical expertise with a collaborative, customer‑centric approach, Aragen serves as a trusted long‑term partner for biologics innovators and biosimilar developers worldwide.